EP3822268A1 — Substituted hydantoinamides as adamts7 antagonists
Assigned to Bayer AG · Expires 2021-05-19 · 5y expired
What this patent protects
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, c…
USPTO Abstract
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty.R <sup>1</sup> is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 10-membered heteroaryl or phenyl; R <sup>2</sup> is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R <sup>3</sup> , R <sup>4</sup> , R <sup>5</sup> , R <sup>6</sup> , R <sup>7</sup> , R <sup>8</sup> are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R <sup>2</sup> , R <sup>3</sup> , R <sup>4</sup> is H; X <sup>1</sup> , X <sup>2</sup> , X <sup>3</sup> , X <sup>4</sup> , X <sup>5</sup> , X <sup>6</sup> are independently N or C; with the proviso that in each ring maximal one X is N.
Drugs covered by this patent
- Verquvo (VERICIGUAT) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.